Hyperlipidemia, Familial Combined, 3, also known as familial combined hyperlipidemia, is related to hyperlipidemia, familial combined, 1 and hypercholesterolemia, familial, 2. An important gene associated with Hyperlipidemia, Familial Combined, 3 is LPL (Lipoprotein Lipase), and among its related pathways/superpathways are Metabolism and Olfactory Signaling Pathway. The drugs Fenofibrate and Lovastatin have been mentioned in the context of this disorder. Affiliated tissues include heart and liver, and related phenotypes are xanthelasma and myocardial infarction